Medical Design Briefs - October 2024 - 11

engineering to create a bold new world
of drug-delivery technologies. These
researchers pioneered the first transdermal
patches for motion sickness,
diabetes, contraception and smoking
cessation before joining Grand Rapids,
MI-based Corium Innovations.
Nearly a quarter of a century of transdermal
innovations has led Corium Innovations
to develop nearly 100 patents covering
a wide range of scientific research in
drug delivery, including applications for
transdermal, polymer, and permeation
enhancement technologies, as well as 35
published scientific papers and more than
40 partnerships with different clients.
And in so doing, the Corium Innovations
team advanced the science of
transdermal technology with Corplex®
,
a flexible, groundbreaking transdermal
drug-delivery innovation platform with a
proprietary mix of adhesives, polymers,
and liners that can be adjusted for almost
any use situation.
Corplex, helping millions of consumers
and patients, is used in Crest White Strips,
Clonidine for hypertension for Dr. Reddy's,
Twirla for contraception for Agile Therapeutics,
and Adlarity, the first and only seven-day
continuous treatment patch for Alzheimer's
disease. Corium Innovations joins
a 45-year short list of indications available in
a transdermal patch form. The list includes:
* Hypertension
* Local anesthesia
* Angina pectoris
* Motion sickness
* Pain
* Smoking control
* Migraine
* Major depression
* Parkinson disease
* Alzheimer disease
* ADHD
Adlarity: Instantly Converting
Hydrophilic Into Hydrophobic
Unlike most transdermal products,
which can only deliver only hydrophobic
drugs, Corplex is made by Corium
Innovations, the only company that can
deliver HCl salts through the skin. Corplex
makes it possible for hydrophilic
drugs, which are otherwise impossible
to deliver transdermally, to be successfully
delivered by in-situ-free-base conversion
into hydrophobic drugs, which
are transdermally delivered with high
drug utilization, enhanced skin absorption
and low COGs.
Medical Design Briefs, October 2024
Adlarity is a once-weekly treatment for Alzheimer's dementia. (Credit: Corium Innovations)
The Corplex technology advance
makes it possible to treat mild, moderate,
or severe dementia of the Alzheimer's
type with Adlarity®
, the first
and only FDA-approved once-weekly
transdermal system that consistently
delivers the molecule Donepezilhydrochloride.
Because Corplex
con verts the molecule Donepezilhydrochloride
in-situ into a freebase,
Corplex enables the bioavailability or
the absorption of that particular drug.
to shoot up like a rocket.
www.medicaldesignbriefs.com
Corplex and other conventional
transdermal patches that are made for
hydrophobic drugs can go through the
skin more effectively. Corplex can control
that flux or plasma concentration
can control the permeation by using
permission enhancers and adjusting
pH, etc. So, there's a design aspect
that is relevant that the company can
potentially pursue in hydrophobic
moieties, but in addition to that, Corplex
can handle hydrophilic drugs
that others can't.
11
Layer 6: Release Liner
The seven-day multi-layer Adlarity patch delivers in a dose-proportional manner. (Credit: Corium Innovations)
Layer 1: Overlay
Backing
Adhesive
Layer 2: Separating Layer
Layer 3: Drug Matrix
Layer 4: Microporous Membrane
Layer 5: Contact Adhesive

https://www.medicaldesignbriefs.com

Medical Design Briefs - October 2024

Table of Contents for the Digital Edition of Medical Design Briefs - October 2024